No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Nkarta 13G Filing Shows Citadel Advisors Reported A 5.4% Stake In The Co As Of December 6, 2024
Express News | Kenneth Griffin Reports 5.4% Passive Stake in Nkarta as of Dec 6 - SEC Filing
Nkarta Opens Enrolment, Receives Clearance for Autoimmune Diseases Therapy Trials
Express News | Nkarta Inc: Clinical Data From Ntrust-1 and Ntrust-2 Planned for 2025
Express News | Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2